Numinus Wellness Inc., a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce Cedar Clinical Research is a top research site for MindMed’s Phase 2b study evaluating MM-120 for General Anxiety Disorder.

This is sponsored content issued on behalf of Numinus Wellness, please see full disclaimer here.


More From The Market Online

Avicanna launches 10% CBD (THC free) formula in Canada

Avicanna (TSX:AVCN) launches RHO Phyto Micro Drop 100, a 10 per cent CBD (THC free), proprietary oral formulation in Canada.

Theratechnologies phases down preclinical oncology research

Biopharmaceutical company Theratechnologies (TSX:TH) announced it will phase down its preclinical oncology research activities.